According to the Market Statsville Group (MSG), the global alcoholic liver diseases treatment market size is expected to grow from USD 1795.57 million in 2022 to USD 3235.79 million by 2033, at a CAGR of 5.5% from 2023 to 2033. Alcohol-related liver disease (ALD) is caused by consuming more alcohol than the liver can handle, causing damage to the organ. The liver, which is in responsible of several biological functions, processes what the body requires while eliminating what it does not require. The chemical process that occurs as the liver breaks down the alcohol generates a toxin that damages liver cells. Several factors contribute to the increase in consumption, including rising disposable income and a growing urban population. Rising urbanization, increased access and advertising have all contributed to higher alcohol consumption. This will boost the market for the forecasting period. On the other hand, the side effects associated with medications are expected to hamper the growth of the Alcoholic Liver Diseases Treatment market during the overall forecast period. Moreover, the government is focused on the R&D development of novel therapies to treat liver diseases, creating a lucrative growth opportunity for the market.

Definition of the Global Alcoholic Liver Diseases Treatment Market

Alcoholic Liver Disease includes a broad clinical-histological spectrum from simple steatosis, cirrhosis, and acute alcoholic hepatitis with or without cirrhosis to hepatocellular carcinoma as a complication of cirrhosis. The pathogenesis of ALD can be conceptually divided into Ethanol mediated liver injury, Inflammatory Immune response to injury, Intestinal permeability, and microbiome changes. Corticosteroids may improve outcomes, but this is controversial and probably only impacts short-term survival. New pathophysiology-based therapies, including IL22, anakinra, and others, are under study.

More than 22,000 people die annually in the United States from Alcoholic Liver Disease (ALD). Nearly 75% of those deaths are mostly men, yet women develop the disease after less exposure to alcohol than men. Following an ALD diagnosis, the most important thing to take is abstinence. The only method to possibly repair the damage or prevent the sickness from progressing is to avoid alcohol. Those who have difficulty quitting drinking may have alcohol use disorder (AUD) and should consult a doctor about treatment options. Getting treatment promotes long-term abstinence and reduces the risk of serious withdrawal symptoms, including hallucinations and seizures, for which medication may be administered.

COVID-19 Impact on the Global Alcoholic Liver Diseases Treatment Market

Since the virus that causes Covid-19 was discovered, it has spread from its origin in Wuhan, China, to other parts of the world. As a result, the Coronavirus has spread around the world, not just in Asia. As a result of the COVID-19 pandemic, alcohol sales and consumption increased, but the impact of this increase on the health of the population is not fully understood. Scientists used data from a national survey of U.S. adults regarding their drinking habits to simulate the drinking trajectories and liver disease trends of all U.S. adults during the COVID-19 pandemic. They calculated that an increase in alcohol intake of one year during the COVID-19 pandemic would result in 8,000 more fatalities from alcohol-related liver disease, 18,700 incidents of liver failure, and 1,000 cases of liver cancer by 2040. In the short term, COVID-19-related increases in alcohol consumption are predicted to result in 100 extra fatalities and 2,800 additional instances of liver disease by 2023. Effects of the COVID-19 pandemic unrelated to SARS-CoV-2 infection itself may prove to have the biggest effect on patients with ALD. Undoubtedly, COVID-19 will enact massive collateral damage through the effects of deferred care, medication nonadherence, increased consumption of food, and more high-risk alcohol use.

Global Alcoholic Liver Diseases Treatment Market Dynamics

Drivers: Increasing alcohol consumption and unhealthy diets

Consumption growth may be linked to a variety of causes, including increased disposable income and a growing urban population, among others. Alcohol use has grown as a result of rising urbanization, better access, and advertising. It should also be emphasized that alcohol taxes are the most important source of revenue for numerous governments. Alcohol penetration and frequency are increasing as a result of shifts in societal acceptance, urbanization, female empowerment, increased affluence, and product developments. After two years of pandemic-induced isolation, a growing number of young adults, particularly in cities, are increasingly mingling at restaurants, clubs, pubs, and bars. And, with the festive season approaching in nations such as India and China, alcohol corporations are creating and selling additional products in order to generate bigger sales and maximize profits.

Restraints: Side effects associated with medications and poor diagnosis facilities

The side effects associated with medications are expected to hamper the growth of the Alcoholic Liver Diseases Treatment market during the overall forecast period. The higher the dose of prednisolone that patients take and the longer they take it, the greater the chance of side effects. Side effects, such as mood changes or stomach upset, dizziness, fast, slow, pounding, or irregular heartbeat or pulse, weight gain, can happen straight away. Others, such as getting a rounder face, happen after weeks or months.

There may be side effects that may not require any medical treatment. These adverse effects may fade as the body responds to the medication. Also, the healthcare professional may be able to talk about ways to prevent or reduce some of these side effects. Further, the side effects of pentoxifylline are nausea, vomiting, bloating, upset stomach, dizziness, headache, chest pain, severe allergic reaction, low red blood cell count, leukaemia and many more.  

Opportunities: R&D funding by governments for the development of novel therapies to treat chronic liver disease

Liver disease doesn't usually cause any obvious signs or symptoms until it is fairly advanced, and the liver is damaged. Thus, government is focused on R&D development of novel therapies to treat liver diseases creating a lucrative growth opportunity for the market. The IVH is continued to focus on therapeutics for viruses such as HIV and SARS-CoV-2, it is also important that they research innovations that can combat devastating chronic illnesses, such as liver disease and kidney dysfunction. There is an urgent need for an effective therapy to treat HRS caused by severe alcoholic hepatitis and cirrhosis. Thus, growing fundings for the development of novel therapies to treat liver diseases fostered the market’s growth over the forthcoming period.

Scope of the Global Alcoholic Liver Diseases Treatment Market

The study categorizes the alcoholic liver diseases treatment market based on indication, treatment, and distribution channel area at the regional and global levels.

By Indication Outlook (Sales, USD Billion, 2019-2033)

• Alcoholic Hepatitis
• Alcoholic Steatohepatitis (Fatty Liver)
• Alcoholic Liver Fibrosis
• Alcoholic Liver Cirrhosis

By Treatment Outlook (Sales, USD Billion, 2019-2033)

• Pentoxifylline
• Glucocorticosteroids
  • Prednisone
  • Triamcinolone
  • Prednisolone
• Betaine
• Other Treatments

By Distribution Channel Outlook (Sales, USD Billion, 2019-2033)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region Outlook (Sales, USD Billion, 2019-2033)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Northern Africa
  • Rest of MEA

Alcoholic Hepatitis segment accounts for the largest market share by Indication

Based on the indication, the market is bifurcated into alcoholic hepatitis, alcoholic steatohepatitis (fatty liver), alcoholic liver fibrosis and alcoholic liver cirrhosis. The alcoholic hepatitis segment is expected to dominate the market share in 2022 in the global alcoholic liver diseases treatment market. In addition, the financial and healthcare burden caused due to alcoholic hepatitis continues to move in the upward curve. Over the past decade, a huge amount of research and development activities has been carried out to improve diagnostic care and quality of treatments. At present, with increasing knowledge pertaining to pathophysiology, new treatment alternatives for alcoholic hepatitis are expected to make an entry into the alcoholic liver disease treatment market. The socioeconomic status of different regions of the world is another major factor that has played a key role in dictating the prevalence of alcohol-related digestive diseases.

North America is expacted to account for the highest market share by Region

Based on the regions, the global poke foods industry market has been segmented across Asia-Pacific, Europe, North America, Middle East & Africa and South America. North America is projected to account the highest market share in 2022. It is due to increase in consumption of alcohol. Alcoholism is a major cause of disease and has important social and economic effects. Alcohol abuse can also cause harm to others, including family members, acquaintances, coworkers, and strangers. And it create a lots of diseases such as alcoholic liver disease, liver disease, alcoholic hepatitis, alcoholic steatohepatitis (fatty liver), alcoholic liver fibrosis, alcoholic liver cirrhosis and many more and due to consumption of these the market will grow in this region.

Key Market Players in the Global Alcoholic Liver Diseases Treatment Market

The alcoholic liver diseases treatment market is significant competitors and extremely cutthroat in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.

Major key players in the global alcoholic liver diseases treatment market are:

• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc.
• Pfizer Inc.
• Novartis AG
• Akorn Operating Company LLC
• Johnson & Johnson Services, Inc.
• Wellona Pharma
• Teva Pharmaceuticals USA, Inc.
• Tianjin Jinjin Pharmaceutical Co. Ltd
• AdvaCare Pharma

Key Issues Addressed

• What is the market size by various segmentation of the alcoholic liver diseases treatment by region and its respective countries?
• What are the customer buying behavior, key takeaways, and Porter's 5 forces of the alcoholic liver diseases treatment market?
• What are the key opportunities and trends for manufacturers involved in the alcoholic liver diseases treatment supply chain?
• What are the fundamental dynamics (drivers, restraints, opportunities, and challenges) of the market?
• What and how regulations, schemes, patents, and policies are impacting the growth of the market?
• What are the upcoming technological solutions influencing market trends? How will existing companies adapt to the new change in technology?
• The market player positioning, top winning strategies by years, company product developments, and launches will be?
• How has COVID-19 impacted the demand and sales of alcoholic liver diseases treatment in the global market? Also, the expected BPS drop or rise count of the market and market predicted recovery period.
• Detailed analysis of the competitors and their latest launch, and what are the prominent startups introduced in the target market? Also, detailed company profiling of 25+ leading and prominent companies in the market.